HER2+ Breast Cancer

Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.

Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Charles Powell, MD, MBA, discusses managing fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Bhuvaneswari Ramaswamy, MD, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

Elyse Lower, MD, discusses the impact of tucatinib on the treatment of patients with HER2-positive breast cancer.

Despite a modest central nervous system overall response rate, the combination of pertuzumab and high-dose trastuzumab was found to induce clinical benefit in 68% of patients with HER2-positive metastatic breast cancer enrolled to the phase 2 PATRICIA trial.

Robert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Although fewer deaths were reported with neratinib in patients with HER2-positive breast cancer treated on the phase 3 ExteNET trial, the agent was not found to result in a significant improvement in overall survival after 8 years of follow-up.

Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.

Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

Jane L. Meisel, MD, discusses sequencing therapies for patients with metastatic HER2-positive breast cancer.

The National Institute for Health and Care Excellence has published draft guidance that recommends fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer following 2 or more anti-HER2 therapies.

Jane L. Meisel, MD, discusses the potential utility of CDK4/6 inhibitors in HER2-positive metastatic breast cancer.

As longer-term follow-up data become available for several agents approved for HER2-positive metastatic breast cancer, investigators are looking closely at the characteristics of patients enrolled in those clinical trials to determine appropriate treatment strategies in the third-line setting and beyond.

Mei Wei, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Jane L. Meisel, MD, discusses sequencing questions, tucatinib combinations under exploration, and emerging strategies for use in the treatment of patients with HER2-positive breast cancer.

Jane L. Meisel, MD, discusses managing toxicities associated with ado-trastuzumab emtansine in patients with HER2-positive breast cancer.

Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.

Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.

Jane L. Meisel, MD, discusses some of the nuances of utilizing adjuvant ado-trastuzumab emtansine in HER2-positive breast cancer.